文献速递白血病淋巴瘤

分化依赖的EBF1活性决定CD22转录及白血病对奥加伊妥珠单抗的敏感性

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin.
PubMed 文献 · Blood · 2025-01-01

研究通过196例人B-ALL样本的多组学分析与体外奥加伊妥珠单抗(InO)敏感性检测,发现白血病分化阻滞于pre-pro-B阶段与InO耐药相关,EBF1是CD22表达的关键调控因子,EBF1结合位点染色质开放状态差异与InO敏感性相关,BCR::ABL1 ALL亚型内EBF1转录下调或体细胞改变导致CD22表达降低及InO耐药。

要点

  • 196例B-ALL多组学分析显示分化阻滞于pre-pro-B阶段与InO耐药相关。
  • 筛选1639个转录因子基因确定EBF1为CD22表达关键调控因子(FDR 7.1×10-4)。
  • CRISPRi靶向CD22位点EBF1结合位点使细胞表面CD22降低约50倍、InO耐药增加约22倍。

核心结论

  • EBF1在B细胞发育过程中直接影响CD22表达,进而导致InO反应的患者间差异,即使在同一B-ALL亚型内亦如此。

研究设计与样本

  • 对196例人B-ALL样本进行多组学表征,并结合体外InO敏感性分析。
  • 对1639个转录因子基因进行筛选以鉴定CD22表达调控因子。
  • 比较最InO敏感与最耐药病例(50%致死浓度<第10百分位 vs >第90百分位,n=18)的ATAC-seq图谱。
  • 在ALL细胞系中使用CRISPR干扰靶向CD22位点的EBF1结合位点。

主要发现

  • 白血病早期分化阻滞于pre-pro-B阶段与InO耐药相关。
  • EBF1被鉴定为CD22表达的关键调控因子,假发现率为7.1×10-4。
  • 最InO敏感与最耐药病例比较,EBF1结合基序在染色质开放状态差异区域显著富集(P=8×10-174)。
  • CRISPRi靶向CD22位点EBF1结合位点导致细胞表面CD22表达降低约50倍,InO耐药增加约22倍。
  • 在BCR::ABL1 ALL中观察到与EBF1转录下调(P=1.1×10-15)和/或体细胞改变(P=.004)相关的亚型内异质性,导致CD22表达降低(P=8.3×10-11)及体外和体内InO耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with high efficacy in lymphoid malignancies. It targets the B-cell surface protein CD22, which is expressed in most B-cell acute lymphoblastic leukemia (B-ALL) cases, albeit with variable intensity. However, factors governing CD22 expression and thus leukemia sensitivity to InO remain incompletely understood. Using multiomic characterization of 196 human B-ALL samples, coupled with ex vivo InO sensitivity profiling, we showed that early leukemia differentiation arrest at the pre-pro-B stage is associated with resistance to InO. Screening of 1639 transcription factor genes identified early B-cell factor 1 (EBF1) as a key regulator of CD22 expression (false discovery rate of 7.1 × 10-4). When comparing the assay for transposase-accessible chromatin with sequencing profiling results of the most InO-sensitive and -resistant cases (50% lethal concentration <10th vs >90th percentile, n = 18), the binding motif for EBF1 was strikingly enriched in regions with differential open chromatin status (P = 8 × 10-174). CRISPR interference targeting EBF1 binding sites at the CD22 locus led to an ∼50-fold reduction in cell surface CD22 expression and, consequently, an ∼22-fold increase in InO resistance in ALL cell lines. Interestingly, within BCR::ABL1 ALL, we observed intrasubtype heterogeneity linked to EBF1 transcriptional downregulation (P = 1.1 × 10-15) and/or somatic alteration (P = .004), which led to reduced CD22 expression (P = 8.3 × 10-11) and ex vivo and in vivo resistance to InO. Collectively, these findings point to the direct impact of EBF1 on CD22 expression during B-cell development, which, in turn, contributes to interpatient variability in InO response, even within the same subtype of B-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Escherich CS, Li Z, Barnett KR, et al. Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood. 2025. PMID: 40435412. doi:10.1182/blood.2024028215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。